약물 스크리닝 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 검체별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Drug Screening Market Summary

The global drug screening market size was estimated at USD 11.08 billion in 2025 and is projected to grow from USD 11.80 billion in 2026 to USD 19.09 billion by 2033, at a CAGR of 7.12% from 2026 to 2033. The North America drug screening industry accounted for the largest revenue share of 38.60% in 2025.

The growth of the market is attributed to the rising substance abuse, stringent regulations, government funding, technological advancements, and increasing demand for substance testing across sectors like healthcare and sports, driven by the need for effective substance abuse detection and management.

Global Drug Screening Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global drug screening market report based on product, sample, end use, and region.

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Instruments
  • Immunoassays Analyzers
  • Chromatography Instruments
  • Breath Analyzer
  • Fuel Cell Breath Analyzer
  • Semi-Conductor Breath Analyzer
  • Others Breath Analyzer
• Rapid Testing Devices
  • Urine Testing Devices
  • Drug Testing Cups
  • Dip Cards
  • Drug Testing Cassettes
  • Oral Fluid Testing Devices
• Consumables
  • Assay Kits
  • Sample Collection Devices
  • Calibrators & Controls
  • Other Consumables
• Services and Others
• Sample Outlook (Revenue, USD Billion, 2021 - 2033)
• Urine Samples
• Breath Samples
• Oral Fluid Samples
• Hair Samples
• Other Samples
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Criminal Justice & Law Enforcement Agencies
• Workplaces
• Drug Treatment Centers
• Individual Users
• Pain Management Centers
• Schools & Colleges
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Sample Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
  • 1.3.1. Objectives
  • 1.3.2. Objective - 1
  • 1.3.3. Objective - 2
  • 1.3.4. Objective - 3
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product & Sample type Snapshot
• 2.3. End Use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Increasing drug and alcohol consumption
  • 3.2.3. Growing demand for drug screening measures
  • 3.2.4. Rise in government funding
  • 3.2.5. Market Restraint Analysis
    • 3.2.5.1. Rising false positive and negative results in drug screeni9ng limits screening process
    • 3.2.5.2. Rise in privacy concerns limiting the expansion of drug screening practices
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

• 4.1. Drug Screening Market: Technology Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.2.2. Immunoassays Analyzers
    • 4.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.2.3. Chromatography Instruments
    • 4.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.2.4. Breath Analyzer
    • 4.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.2.4.2. Fuel Cell Breath Analyzer
      • 4.2.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.2.4.3. Semi-Conductor Breath Analyzer
      • 4.2.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.2.4.4. Others Breath Analyzer
      • 4.2.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.3. Rapid Testing Devices
  • 4.3.1. Rapid testing devices market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.3.2. Urine Testing Devices
    • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.3.2.2. Drug Testing Cups
      • 4.3.2.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.3.2.3. Dip Cards
      • 4.3.2.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
    • 4.3.2.4. Drug Testing Cassettes
      • 4.3.2.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.3.3. Oral Fluid Testing Devices
    • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.4. Consumables
  • 4.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.4.2. Assay Kits
    • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.4.3. Sample Collection Devices
    • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.4.4. Calibrators & Controls
    • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.4.5. Other Consumables
    • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.5. Services and Others
  • 4.5.1. Services and others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Sample Business Analysis

• 5.1. Drug Screening Market: Sample Movement Analysis
• 5.2. Urine Samples
  • 5.2.1. Urine samples market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.3. Breath Samples
  • 5.3.1. Breath samples market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.4. Oral Fluid Samples
  • 5.4.1. Oral fluid samples market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.5. Hair Samples
  • 5.5.1. Hair samples market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.6. Other Samples
  • 5.6.1. Other samples market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 6. End Use Business Analysis

• 6.1. Hospitals
  • 6.1.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.2. Criminal Justice & Law Enforcement Agencies
  • 6.2.1. Clinical laboratories market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.3. Workplaces
  • 6.3.1. Workplaces market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.4. Drug Treatment Centers
  • 6.4.1. Drug treatment centers market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.5. Individual Users
  • 6.5.1. Individual users market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.6. Pain Management Centers
  • 6.6.1. Pain management centers market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.7. Schools & Colleges
  • 6.7.1. Schools & Colleges market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.8. Others
  • 6.8.1. Others market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 7. Regional Business Analysis

• 7.1. Drug Screening Market Share By Region, 2025 & 2033
• 7.2. North America
  • 7.2.1. SWOT Analysis
  • 7.2.2. North America Drug Screening Market, 2021-2033 (USD Billion)
  • 7.2.3. U.S.
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. U.S. Drug Screening Market, 2021-2033 (USD Billion)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Target Disease Prevalence
    • 7.2.4.3. Competitive Scenario
    • 7.2.4.4. Regulatory Framework
    • 7.2.4.5. Mexico Drug Screening Market, 2021-2033 (USD Billion)
  • 7.2.5. Canada
    • 7.2.5.1. Key Country Dynamics
    • 7.2.5.2. Target Disease Prevalence
    • 7.2.5.3. Competitive Scenario
    • 7.2.5.4. Regulatory Framework
    • 7.2.5.5. Canada Drug Screening Market, 2021-2033 (USD Billion)
• 7.3. Europe
  • 7.3.1. SWOT Analysis
    • 7.3.1.1. Europe Drug Screening Market, 2021-2033 (USD Billion)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. Regulatory Framework
    • 7.3.2.5. UK Drug Screening Market, 2021-2033 (USD Billion)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Germany Drug Screening Market, 2021-2033 (USD Billion)
  • 7.3.4. Spain
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Spain Drug Screening Market, 2021-2033 (USD Billion)
  • 7.3.5. France
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. France Drug Screening Market, 2021-2033 (USD Billion)
  • 7.3.6. Italy
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Italy Drug Screening Market, 2021-2033 (USD Billion)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Denmark Drug Screening Market, 2021-2033 (USD Billion)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Sweden Drug Screening Market, 2021-2033 (USD Billion)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Norway Drug Screening Market, 2021-2033 (USD Billion)
• 7.4. Asia Pacific
  • 7.4.1. SWOT Analysis
    • 7.4.1.1. Asia Pacific Drug Screening Market, 2021-2033 (USD Billion)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Regulatory Framework
    • 7.4.2.5. Japan Drug Screening Market, 2021-2033 (USD Billion)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. China Drug Screening Market, 2021-2033 (USD Billion)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. India Drug Screening Market, 2021-2033 (USD Billion)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. South Korea Drug Screening Market, 2021-2033 (USD Billion)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Australia Drug Screening Market, 2021-2033 (USD Billion)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Thailand Drug Screening Market, 2021-2033 (USD Billion)
• 7.5. Latin America
  • 7.5.1. SWOT Analysis
    • 7.5.1.1. Latin America Drug Screening Market, 2021-2033 (USD Billion)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. Regulatory Framework
    • 7.5.2.5. Brazil Drug Screening Market, 2021-2033 (USD Billion)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Argentina Drug Screening Market, 2021-2033 (USD Billion)
• 7.6. MEA
  • 7.6.1. SWOT Analysis
    • 7.6.1.1. MEA Drug Screening Market, 2021-2033 (USD Billion)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Regulatory Framework
    • 7.6.2.5. South Africa Drug Screening Market, 2021-2033 (USD Billion)
  • 7.6.3. UAE
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. UAE Drug Screening Market, 2021-2033 (USD Billion)
  • 7.6.4. Saudi Arabia
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Saudi Arabia Drug Screening Market, 2021-2033 (USD Billion)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. Kuwait Drug Screening Market, 2021-2033 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2022
• 8.4. Company Profiles/Listing
  • 8.4.1. Abbott
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.1.3. Technology Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Quest Diagnostics Incorporated
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.2.3. Technology Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. F. Hoffmann-La Roche Ltd
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.3.3. Technology Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Thermo Fisher Scientific Inc
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.4.3. Technology Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Siemens Healthcare AG
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.5.3. Technology Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Laboratory Corporation of America Holdings
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.6.3. Technology Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Alfa Scientific Designs, Inc.,
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.7.3. Technology Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. OraSure Technologies, Inc
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.8.3. Technology Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Omega Laboratories, Inc.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.9.3. Technology Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Dragerwerk AG & Co. KGaA
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.10.3. Technology Benchmarking
    • 8.4.10.4. Strategic Initiatives
  • 8.4.11. Bio-Rad Laboratories, Inc.
    • 8.4.11.1. Overview
    • 8.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.11.3. Technology Benchmarking
    • 8.4.11.4. Strategic Initiatives